Detalhe da pesquisa
1.
Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19.
Antimicrob Agents Chemother
; 67(1): e0135322, 2023 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519929
2.
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
PLoS Pathog
; 11(5): e1004932, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26023780
3.
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults.
Infect Dis Ther
; 12(5): 1365-1377, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37185797
4.
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE).
Open Forum Infect Dis
; 10(7): ofad314, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37496612
5.
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.
Sci Transl Med
; 15(688): eadg2783, 2023 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36947596
6.
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron.
Open Forum Infect Dis
; 10(6): ofad279, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351456
7.
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.
medRxiv
; 2022 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36299436
8.
Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
Antiviral Res
; 184: 104763, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32151645
9.
Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
EBioMedicine
; 40: 574-582, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30638863
10.
Extending human IgG half-life using structure-guided design.
MAbs
; 10(7): 1098-1110, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29947573
11.
A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
PLoS One
; 8(8): e72054, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23991039
12.
Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.
PLoS One
; 8(1): e52732, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23326351